natgillin/translations-raw huggingface dataset:
A method for stimulating the growth of plants according to claim 7 characterized in that the strain of Tsukamurella paurometabola is strain C-924. 
Metoda stimuliranja rasta biljaka prema zahtjevu 7, naznačena time da je soj Tsukamurella paurometabola soj C-924.
A method for stimulating the growth of plants according to claim 7 or 8 characterized in that the effective amount of the biofertilizer agent to be applied to the soil, or substrate in an aqueous suspension is in a concentration of approximately between 106 and 109 cfu per milliliter of suspension. 
Metoda stimuliranja rasta biljaka prema zahtjevu 7 ili 8, naznačena time da je učinkovita količina biognojivog sredstva koje se primjenjuje na zemljištu, ili supstrata u vodenoj suspenziji u koncentraciji između otprilike 106 i 109 cfu po mililitru suspenzije.
An isolated antibody or antigen-binding fragment thereof that binds to a free C5a polypeptide, wherein the free C5a is a human polypeptide (hC5a) having the amino acid sequence depicted in SEQ ID NO:1, and wherein the antibody or antigen-binding fragment thereof binds to the free hC5a polypeptide in vitro with a KD that is less than 1.25 x 10-9 M as measured by surface plasmon resonance (SPR) in the presence of a molar excess of uncleaved, native human C5, and wherein the antibody or antigen-binding fragment thereof comprises: 
Izolirano protutijelo ili njegov fragment koji veže antigen koje se veže na slobodni C5a polipeptid, pri čemu slobodni C5a je ljudski polipeptid (hC5a) koji ima sekvencu aminokiseline prikazanu u SEQ ID NO:1, te pri čemu se protutijelo ili njegov fragment koji veže antigen veže na slobodni hC5a polipeptid in vitro sa KD koji je manji od 1.25 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom (SPR) u prisutnosti molarnog suviška ne rascijepljenog, izvornog ljudskog C5, te je naznačeno time da protutijelo ili njegov fragment koji veže antigen sadrži:
a light chain polypeptide comprising: 
polipeptid lakog lanca koji sadrži:
An isolated monoclonal antibody that specifically binds to a human R-spondin (RSPO) protein and inhibits growth of a solid tumor comprising solid tumor stem cells, wherein the antibody disrupts binding of the RSPO protein to a leucine-rich repeat-containing G protein-coupled receptor (LGR) protein, wherein the LGR protein is LGR5; and/or disrupts RSPO activation of LGR5 signaling. 
Izolirano monoklonalno protutijelo, naznačeno time, da se specifično veže na ljudski protein R-spondin (RSPO-protein) i inhibira rast čvrstog tumora koji obuhvaća matične stanice čvrstog tumora, čime protutijelo prekida vezanje RSPO-proteina na receptor proteina spojenog na G-protein, koji je bogat leukinima s ponavljanjem sadržaja (receptor LGR-proteina), pri čemu LGR-protein je LGR5; i/ili ono prekida aktiviranje RSPO-proteina od LGR5-signaliziranja.
An isolated monoclonal antibody that specifically binds to an extracellular domain of a human leucine-rich repeat-containing G protein-coupled receptor (LGR) protein, wherein the LGR protein is LGR5, and inhibits growth of a solid tumor comprising solid tumor stem cells, wherein the antibody disrupts binding of RSPO to LGR5; and/or disrupts RSPO activation of LGR5 signaling. 
Izolirano monoklonalno protutijelo, naznačeno time, da se specifično veže na izvanstaničnu domenu od receptora LGR-proteina spojenog na G-protein, koji je bogat leukinima s ponavljanjem sadržaja, gdje LGR-protein je LGR5, i ono inhibira rast čvrstog tumora koji sadrži matične stanice čvrstog tumora, te pritom protutijelo prekida vezanje RSPO na LGR5; i/ili prekida RSPO-aktiviranje od LGR5-signaliziranja.
monoclonal antibody 88M1 produced by a hybridoma cell line having ATCC deposit number PTA-9342; or 
monoklonalno protutijelo 88M1 proizvedeno pomoću stanične linije hibridoma koji ima broj ATCC depozita pod oznakom PTA-9342; ili
an isolated antibody comprising the heavy chain CDRs and/or the light chain CDRs of a monoclonal antibody 88M1 produced by a hybridoma cell line having ATCC deposit number PTA-9342; or 
izolirano protutijelo koje sadrži CDR-ove jakog lanca i/ili CDR-ove slabog lanca od monoklonalnog protutijela 88M1 proizvedenog pomoću stanične linije hibridoma koji ima broj ATCC depozita pod oznakom PTA-9342; ili
an isolated antibody that competes with a monoclonal antibody 88M1 produced by a hybridoma cell having ATCC deposit number PTA-9342 in a competitive binding assay. 
izolirano protutijelo koje se natječe u natjecateljskom ispitivanju vezanja, s monoklonalnim protutijelom 88M1 proizvedenim pomoću stanične linije hibridoma koji ima broj ATCC depozita pod oznakom PTA-9342.
A pharmaceutical composition comprising the antibody of any of claims 1 to 8 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 8 i farmaceutski prikladan nosač.
A pharmaceutical composition according to claim 10, further comprising a second anticancer agent. 
Farmaceutski sastav prema zahtjevu 10, naznačen time, da nadalje obuhvaća drugo antitumorsko sredstvo.
An agent for use in treating a cancer comprising cancer stem cells in a human or inhibiting growth of a tumor in a human, the method comprising administering a therapeutically effective amount of an agent that 
Sredstvo, naznačeno time, da se upotrebljava u postupku liječenju raka koji sadrži matične stanice raka za čovjeka, ili u postupku inhibicije rasta tumora kod čovjeka, pri čemu taj postupak obuhvaća davanje terapeutski učinkovite količine sredstva koje vrši:
The agent for use according to claim 16 or claim 17, wherein the human comprises a tumor comprising cancer stem cells or has had a tumor comprising cancer stem cells removed. 
Sredstvo za uporabu prema zahtjevu 16 ili zahtjevu 17, naznačeno time, da čovjek ima tumor koji obuhvaća matične stanice raka ili je čovjeku odstranjen tumor koji je obuhvaćao matične stanice raka.
reacting a compound of formula VII with sodium acetate to produce a compound of formula VI 
reakcija spoja formule VII s natrijevim acetatom, da se proizvode spoj formule VI:
hydrolyzing the product of step (b) to form the hydroxymethyl oxazolidinone compound of formula V 
hidroliziranje proizvoda iz koraka (b) za tvorbu hidroksimetil-oksazolidinona spoja formule V:
The process according to claim 1, wherein the reaction in step (a) is carried out with use of a solvent and at 70-80 °C. 
Postupak prema zahtjevu 1, naznačen time, da se reakcija u koraku (a) provodi uz uporabu otapala i na temperaturi od 70-80 °C.
The process according to claim 1, wherein the chloromethyl oxazolidinone compound of formula VII is converted in the step (b) to the acetyl derivative of compound of formula VI as defined in claim 1, which comprises reacting the said chloromethyl oxazolidinone with anhydrous sodium acetate to give the acetyl compound of formula VI 
Postupak prema zahtjevu 1, naznačen time, da se klorometil-oksazolidinon spoj formule VII, pretvara u koraku (b) u derivat acetila spoja formule VI, kako je definirano u zahtjevu 1, gdje se izvodi reakcija spomenutog klorometil-oksazolidinona s bezvodnim natrijevim acetatom, kako bi se dobio spoj acetila formule VI:
The process according to claim 6, wherein the quantity of sodium acetate is at least 2.0 molar equivalents to compound of formula VII. 
Postupak prema zahtjevu 6, naznačen time, da količina natrijevog acetata iznosi najmanje 2,0 molarna ekvivalenta prema spoju formule VII.
A process for the preparation of Linezolid of formula which comprises: 
Postupak za proizvodnju Linezolida sljedeće formule:
The method according to claim 1, in which the shaped surface of the trenches (14) in contact with the geostrips (20), consists of a fine, inert material, with dimensions equal to or less than 0.5 mm. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se oblikovana površina rovova (14) u kontaktu s geotrakama (20) sastoji od finog, inertnog materijala, veličine jednake ili manje od 0,5 mm.
The method according to claim 3, in which the layer of drainage material (15) comprises a geodrain. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da je sloj drenažnog materijala (15) geodrain.
The method according to claim 1, in which the layer of filtering material (17) is chosen from: lime, sand, fine rounded gravel, geomesh, geotextile or their combination. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se sloj materijala za filtriranje (17) odabire između: vapna, pijeska, fino zaobljenog šljunka, geomreže, geotekstila ili njihove kombinacije.
The device according to claim 9, in which a layer (17) of filtering material comprises: sand, earth, clay, lime, used singly or in combination. 
Uređaj u skladu s patentnim zahtjevom 9, naznačen time, da sloj (17) materijala za filtriranje obuhvaća: pijesak, zemlju, glinu, vapno, koji se koriste pojedinačno ili u kombinaciji.
The device according to claim 11, in which the layer (17) of filtering material further comprises a geotextile, a geomesh, a geocomposite or their combination. 
Uređaj u skladu s patentnim zahtjevom 11, naznačen time, da sloj (17) materijala za filtriranje nadalje sadržava geotekstil, georešetku, geokompozit ili njihovu kombinaciju.
The device according to claim 9, in which the ballast material includes: sand, gravel, earth, concrete or their combination. 
Uređaj u skladu s patentnim zahtjevom 9, naznačen time, da balastni materijal uključuje: pijesak, šljunak, zemlju, beton ili njihovu kombinaciju.
The device according to claim 9, in which the synthetic material of the geostrips (20) is chosen from the materials listed in the following table: TYPE BASIC MATERIAL 
Uređaj u skladu s patentnim zahtjevom 9, naznačen time, da je sintetički materijal geotraka (20) odabran od materijala navedenih u sljedećoj tablici:
The device according to claim 9, characterised by comprising an additional geostrip (23) to cover the ballast material (22, 22A), sealed to the geostrips (20). 
Uređaj u skladu s patentnim zahtjevom 9, naznačen time, da sadržava dodatne geotrake (23) za pokrivanje balastnog materijala (22, 22A), koji je hermetički spojen na geotrake (20).
A system for preparing a beverage comprising: 
Sustav za pripremu napitka koji obuhvaća sljedeće:
a water tank (2); a percolation element (6); 
spremnik za vodu (2); element za cijeđenje (6);
a capsule (7), which is inserted into said percolation element (6) and presents a plurality of infusion chambers (26 and 27), each of which contains a corresponding infuse and present a distinct outlet area; 
kapsulu (7) koja se umeće u navedeni element za cijeđenje (6) i ima veći broj infuzijskih komora (26 i 27), od kojih svaka sadržava odgovarajući proizvod za infuziju i ima odvojeni izlazni prostor;
A system according to any of the previous claims 6, 7, characterised in that it comprises an electronic control unit (13), which is provided with a data setting panel (14) and is suited to control the different elements and devices of the system. 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva 6 i 7, naznačen time, da sadržava elektronički upravljački uređaj (13), koji je opremljen pločom za odabir podataka (14) i pogodan je za kontrolu različitih elemenata i uređaja sustava.
and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached and: . 
i R3 zajedno tvore, s ugljikovim atomima fenilne jezgre na koje su spojeni, 6-člani heterocikal koji sadrži dušik koji odgovara jednoj od formula (A), (B) ili (C) ispod: [image] u kojima valovite crte predstavljaju fenilnu jezgru na koju su spojeni R2 i R3 i: .
Compound according to Claim 1, in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to formula (A) as defined in Claim 1, optionally in the form of a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da R2 i R3 zajedno tvore, s ugljikovim atomima fenilne jezgre na koje su spojeni, 6-člani heterocikal koji sadrži dušik koji odgovara formuli (A) kako je definirano u zahtjevu 1, proizvoljno u obliku njegove farmaceutski prihvatljive soli.
Compound according to one of the preceding claims, selected from the following compounds: 
Spoj prema jednom od prethodnih patentnih zahtjeva, naznačen time da je izabran od slijedećih spojeva:
the urea of formula (IX) is subjected to a cyclization reaction in a basic medium. 
urea s formulom (IX) se podvrgava reakciji ciklizacije u bazičnom mediju.
a reaction of esterification of the compound of formula (VII) is carried out so as to obtain the compound of formula (VIII) 
reakcija esterifikacije spoja s formulom (VII) provodi se tako da se dobije spoj s formulom (VIII) [image]
the compound of formula (XII) is subjected, in the presence of a palladium catalyst, of a ligand and of a base, 
spoj s formulom (XII) se podvrgava, u prisutnosti paladijeva katalizatora, liganda i baze,
to a reaction with phenylboronic or heteroarylboronic or phenylboronate ester or heteroarylboronate ester derivatives according to a Suzuki coupling, 
reakciji sa fenilboratnim ili heteroarilboratnim ili fenilboronatnim esterom ili derivatima heteroarilboronatnog estera u skladu sa Suzuki spajanjem,
a reaction of esterification of the compound of formula (VII) is carried out so as to obtain the compound of formula (VIII) 
reakcija esterifikacije spoja s formulom (VII) se provodi tako da se dobije spoj s formulom (VIII) [image]
the compound (VIII) is subjected to a saponification reaction in order to obtain the compound (XXIV): 
spoj (VIII) se podvrgava reakciji saponifikacije kako bi se dobilo spoj (XXIV): [image]
the compound of formula (X) is subjected, in the presence of a palladium catalyst, of a ligand and of a base, 
spoj s formulom (X) se podvrgava, u prisutnosti paladijeva katalizatora, liganda i baze,
or else to a cyanation reaction with zinc chloride, followed by an acid hydrolysis and by an esterification or a peptide coupling with an amine R5R6NH2, R5 and R6 being defined in Claim 1, 
ili drugačije reakciji cijanacije s cinkovim kloridom, nakon čega slijedi kisela hidroliza i esterifikaciji ili peptidnom spajanju s aminom R5R6NH2, R5 i R6 su definirani u zahtjevu 1,
in order to obtain the compound of formula XIV: 
kako bi se dobilo spoj s formulom XIV: [image]
the compound (XIV) is subjected to a saponification reaction in order to obtain the compound (XXV): 
spoj (XIV) se podvrgava reakciji saponifikacije kako bi se dobilo spoj (XXV): [image]
Compound according to any one of Claims 1 to 7, for use thereof in the treatment and prevention of cancers, in particular carcinomas which have a high degree of vascularization, such as lung, breast, prostate, pancreatic, colon, kidney and oesophageal carcinomas, cancers which induce metastases, such as colon cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas, leukaemias, and also thrombopenias. 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da je za upotrebu za liječenje i sprječavanje karcinoma, naročito karcinoma koji imaju visok stupanj vaskularizacije, kao što su rak pluća, rak dojke, rak prostate, rak gušterače, rak debelog crijeva, rak bubrega i ezofagealni karcinomi, te karcinomi koji induciraju metastaze, kao što su rak debelog crijeva, rak jetre i rak želuca, melanomi, gliomi, limfomi, leukemije, te također trombopenije.
The dosage form of claim 1, wherein the pharmaceutically acceptable solubilizer is selected from the group consisting of non-ionic solubilizers, anionic solubilizers and combinations thereof. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da se farmaceutski prihvatljiv solubilizator odabire iz skupine koja se sastoji od neionskih solubilizatora, anionskih solubilizatora i njihove kombinacije.
The dosage form of claim 2, wherein the pharmaceutically acceptable non-ionic solubilizer is selected from the group consisting of polyol fatty acid esters, polyalkoxylated polyol fatty acid esters, polyalkoxylated fatty alcohol ethers, tocopheryl compounds and mixtures of two or more thereof, and wherein the pharmaceutically acceptable anionic solubilizer is selected from the group consisting of alkyl sulfates, alkylcarboxylates, alkylbenzole sulfates and secondary alkane sulfonates. 
Oblik doziranja u skladu s patentnim zahtjevom 2, naznačen time, da se farmaceutski prihvatljiv neionski solubilizator odabire iz skupine koja se sastoji od estera masnih kiselina poliola, estera masnih kiselina polialkoksiliranog poliola, polialkoksiliranih etera masnih alkohola, tokoferilnih spojeva i mješavine dvaju ili više njih i pri čemu je farmaceutski prihvatljiv anionski solubilizator odabran iz skupine koju čine alkil sulfati, alkilkarboksilati, alkilbenzol sulfati i sekundarni alkan sulfonati.
The dosage form of claim 1, wherein the pharmaceutically acceptable solubilizer is selected from the group consisting of tocopheryl compounds having a polyalkylene glycol moiety, sorbitan fatty acid esters and polyoxyethylene sorbitan fatty acid esters. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da se farmaceutski prihvatljiv solubilizator odabire iz skupine koja se sastoji od tokoferilnih spojeva koji imaju polialkilen glikol skupinu, estere masnih kiselina sorbitana i estere masnih kiselina polioksietilen sorbitana.
The dosage form of claim 1, wherein the pharmaceutically acceptable solubilizer comprises at least one of alpha tocopheryl polyethylene glycol succinate, sorbitan monolaurate and polyoxyethylene sorbitan monolaurate. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da farmaceutski prihvatljiv solubilizator sadržava barem jedno od sljedećeg: alfa tokoferil polietilen glikol sukcinat, sorbitan monolaurat i polioksietilen sorbitan monolaurat.
The dosage form of claim 1, containing a non-volatile solvent for the pharmaceutically active ingredient, said solvent being liquid at ambient temperature. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da sadržava neisparivo otapalo za farmaceutski aktivne tvari, a navedeno otapalo tekuće je na sobnoj temperaturi.
The dosage form of claim 1, comprising less than 0.9% by weight of sulfoxide decomposition products of the active ingredient, relative to the weight of the active ingredient. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da sadržava manje od 0,9 % masenih udjela sulfoksidnih proizvoda razgradnje aktivne tvari, u odnosu na masu aktivne supstance.
allowing the melt to solidify to obtain a solid dispersion product. 
skrućivanje taline radi dobivanja proizvoda u obliku čvrste disperzije.
A method for the manufacture of Lactobacillus reuteri cells having reuterin retained within the cells, comprising: 
Metoda proizvodnje stanica Lactobacillus reuteri koje imaju sačuvan reuterin unutar stanica, koja sadrži:
manufacturing Lactobacillus reuteri cell cultures, wherein manufacturing comprises fermenting said cell cultures; 
proizvodnju staničnih kultura Lactobacillus reuteri, gdje proizvodnja sadrži fermentiranje navedenih staničnih kultura;
adding 1,2-propanediol or glycerol to the Lactobacillus reuteri cell cultures at the start of the fermentation, thereby priming the reuterin producing machinery of the Lactobacillus reuteri cells; 
dodavanje 1,2-propandiola ili glicerola staničnim kulturama Lactobacillus reuteri na početku fermentacije, pripremajući na taj način mehanizam proizvodnje reuterina kod stanica Lactobacillus reuteri;
adding glycerol to the Lactobacillus reuteri cell cultures during manufacture, thereby obtaining Lactobacillus reuteri cells having reuterin retained within the cells; and preserving the Lactobacillus reuteri cells by freeze-drying the cell cultures after fermenting. 
dodavanje glicerola staničnim kulturama Lactobacillus reuteri u tijeku proizvodnje, osiguravajući na taj način da stanice Lactobacillus reuteri imaju sačuvan reuterin u stanicama; i konzerviranje stanica Lactobacillus reuteri pomoću liofilizacije staničnih kultura nakon fermentacije.
The method of claim 1, wherein about 1 to about 500 mM of glycerol is added after the fermenting step but before the freeze-drying in the manufacturing process. 
Metoda prema patentnom zahtjevu 1, naznačena time da je oko 1 do oko 500 mM glicerola dodano u proizvodnom procesu nakon koraka fermentacije ali prije liofilizacije.
The product according to claim 6, for use in the treatment of disorders induced by pathogens of the cutaneous system. 
Proizvod prema patentnom zahtjevu 6, naznačen time da je za upotrebu u liječenju poremećaja uzrokovanih patogenima kožnog sustava.
A pharmaceutical composition comprising a product according to claim 6. 
Farmaceutski sastav koji sadrži proizvod prema patentom zahtjevu 6.
stirring a mixture of olivetol, zinc chloride and anhydrous dichloromethane at 40°C for one hour, adding a solution of the (-)-p-menth-2,8-dien-1-ol and anhydrous dichloromethane drop-wise over 1 hour at 40°C to the stirred olivetol-containing mixture, and stirring the resulting mixture for an additional 40 minutes at 40°C, 
miješanje smjese olivetola, cinkovog klorida i bezvodnog diklorometana na 40°C tijekom jednog sata, dodavanje otopine (-)-p-ment-2,8-dien-1-ola i bezvodnog diklorometana kap po kap tijekom 1 sata na 40°C u miješanu smjesu koja sadrži olivetol, te miješanje nastale smjese tijekom dodatnih 40 minuta na 40°C,
cooling the mixture to -10°C, adding a solution of BF3·Et2O in anhydrous dichloromethane drop-wise over 1 hour at -10°C, and stirring the mixture for 30 minutes at -10°C, and 
hlađenje smjese na -10°C, dodavanje otopine BF3·Et2O u bezvodnom diklorometanu kap po kap tijekom 1 sata na -10°C, te miješanje smjese tokom 30 minuta na -10°C, te
The method of claim 2, wherein the acid catalyst is para-toluenesulfonic acid or BF3·Et2O. 
Postupak prema zahtjevu 2, naznačen time da kiseli katalizator je para-toluensulfonska kiselina ili BF3·Et2O.
stirring a mixture of olivetol, zinc chloride and anhydrous dichloromethane at 40°C for one hour, adding a solution of the (±)-p-menth-2,8-dien-1-ol and anhydrous dichloromethane drop-wise over 1 hour at 40°C to the stirred olivetol-containing mixture, and stirring the resulting mixture for an additional 40 minutes at 40°C, 
miješanja smjese olivetola, cinkovog klorida i bezvodnog diklorometana na 40°C tijekom jednog sata, dodavanje otopine (±)-p-ment-2,8-dien-1-ola i bezvodnog diklorometana kap po kap tijekom 1 sata na 40°C u miješanu smjesu koja sadrži olivetol, i miješanje dobivene smjese tijekom dodatnih 40 minuta na 40°C,
cooling the mixture to -10°C, adding a solution of BF3·Et2O in anhydrous dichloromethane drop-wise over 1 hour at -10°C, and stirring the mixture for 30 minutes at -10°C, and 
hlađenja smjese na -10°C, dodavanje otopine BF3·Et2O u bezvodnom diklorometanu kap po kap tijekom 1 sata na -10°C, i miješanje smjese tijekom 30 minuta na -10°C, i
separating the Δ9-tetrahydrocannabinol from the resulting phase containing the Δ9-tetrahydrocannabinol; and 
razdvajanje Δ9-tertahidrokanabinola iz nastale faze koja sadrži Δ9-tertahidrokanabinol; i
The method of claim 5, wherein the Lewis acid is BF3·Et2O. 
Postupak prema zahtjevu 5, naznačen time da Lewisova kiselina je BF3·Et2O.
adding a solution of BF3·Et2O in anhydrous dichloromethane dropwise with stirring over 1 hour to a solution of (+)-cannabidiol in anhydrous dichloromethane at -5°C, stirring the resultant mixture for 1.5 hours at -5°C, adding the mixture to a mixture of ice and 7% NaHCO3, and isolating from the organic phase the crude trans-(+)-Δ9-tetrahydrocannabinol used in step (2). 
dodavanje otopine BF3·Et2O u bezvodnom diklorometanu kap po kap uz miješanje tijekom 1 sata u otopinu (+)-kanabidiola u bezvodnom diklorometanu na -5°C, miješanje nastale smjese tijekom 1.5 sata na -5°C, dodavanje smjese u smjesu leda i 7% NaHCO3, te izoliranje iz organske faze sirovog trans-(+)-Δ9-tertahidrokanabinola koji je korišten u koraku (2).